ApprovalTrail

Approval · Notice of Compliance 31283 · 2023

PREVNAR 20: Notice of Compliance 31283

Issued July 21, 2023

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number
31283
Date
July 21, 2023
Company
Pfizer Canada UlcKirkland, Quebec, Canada
Product type
Biologic
Submission
Supplement to a New Drug Submission (SNDS), supplement
Submission class
Priority
Reason
New Indication: Prevnar 20 (Pneumococcal 20-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) is indicated for active immunization of infants, children and adolescents from 6 weeks through 17 years of age (prior to the 18th birthday) for the prevention of invasive pneumococcal disease (including sepsis, meningitis, bacteremic pneumonia, pleural empyema and bacteremia) caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F.

Products in this notice

BrandDINStatus today
PREVNAR 20Not yet assigned—

Medicinal ingredients